CSL: +8.51%: A strong 1H22 for CSL relative to market expectations today plus their guidance was positive for the full year. Revenue of $5.81bn was above the $5.56bn expected while 1H22 EBIT of $2.21bn compared well to the $2.03bn forecast for the half and also the $2.96bn pencilled in for the full year. While they said the result would be heavily skewed to the first 6 months, they’ve already banked ~75% of the expected full year earnings making it a low bar to get over. All in all, a good result for our 3rd largest ASX listed company after a difficult year having seen the SP fall 25% from their November high.
scroll
Question asked
Question asked
Question asked
Question asked
Question asked
Question asked
Question asked
Question asked
Question asked
Question asked
Question asked
Question asked
Performance update for March, stocks that drove returns & our current positioning
Close
Friday 26th April – ASX200 -101pts, Newmont (NEM), Resmed (RMD) & Super Retail (SUL)
Close
Market Matters Research Lead Shawn Hickman with David Koch
Close
MM is now bullish CSL
Add To Hit List
Related Q&A
What are MM’s favoured recession proof Healthcare stocks?
How would MM advocate shorting CSL?
Looking at “GARY” stocks
Question on CSL SPP
Technical view on CSL, SHL & NXT
Does MM still like CSL?
Targets for PPT, CPU & CSL
Short term price targets for various stocks
New CBA Hybrid + APX & CSL
CSL
MM’s view on CSL
Questions on CSL, REA & FMG
Relevant suggested news and content from the site
Video
WATCH
Performance update for March, stocks that drove returns & our current positioning
Recorded Tuesday 9th April
Podcast
LISTEN
Friday 26th April – ASX200 -101pts, Newmont (NEM), Resmed (RMD) & Super Retail (SUL)
Daily Podcast Direct from the Desk
Video
WATCH
Market Matters Research Lead Shawn Hickman with David Koch
Recorded Monday 25th March
Members only
UNLOCK MARKET MATTERS NOW
Take a free trial.
No payment details required.